Target Name: MCM2
NCBI ID: G4171
Review Report on MCM2 Target / Biomarker Content of Review Report on MCM2 Target / Biomarker
MCM2
Other Name(s): Cyclin-like 1 | minichromosome maintenance deficient 2 (mitotin) | nuclear protein BM28 | Minichromosome maintenance protein 2 | MITOTIN | minichromosome maintenance protein 2 homolog | Nuclear protein BM28 | BM28 | cyclin-like 1 | DFNA70 | D3S3194 | cell devision cycle-like 1 | DNA replication licensing factor MCM2 | Minichromosome maintenance complex component 2, transcript variant 1 | Minichromosome maintenance protein 2 homolog | cdc19 | Cell devision cycle-like 1 | CDCL1 | MCM2_HUMAN | CCNL1 | minichromosome maintenance complex component 2 | MCM2 variant 1

MCM2: A Key Protein in Cancer Treatment and Understanding

MCM2 (Cyclin-like 1) is a protein that is expressed in various tissues throughout the body. It is a key component of the mitotic spindle, which is a structure that pulls the chromosomes apart during cell division. MCM2 has also been shown to play a role in the regulation of cell growth and the control of cell cycle progression.

One of the key functions of MCM2 is its role in the regulation of the spindle formation and function. In mitosis, the spindle is composed of two interacting tubulin proteins. MCM2 is an important component. It helps tubulin form spindles and plays an important role in spindles. In addition, MCM2 can also control spindle stability and regulate chromosome movement in the spindle.

In addition, MCM2 is also related to the cell cycle. It participates in mitosis and interphase of the cell cycle along with tubulin and spindle proteins. During prophase of mitosis, MCM2 binds to histones and helps histone fibers form spindle complexes. During anaphase of mitosis, MCM2 participates in chromosome segregation and helps chromosomes reassemble. These processes are crucial to ensure the smooth progression of mitosis.

Abnormal expression of MCM2 is closely related to the occurrence and development of various cancers. Studies have found that the expression level of MCM2 is closely related to the prognosis and treatment response of various cancers. For example, MCM2 expression levels are closely related to prognosis and treatment response in breast, colon, and ovarian cancers. In addition, the expression level of MCM2 is also closely related to the progression and treatment response of liver cancer and renal cancer. Therefore, studying the role of MCM2 in the occurrence and development of cancer is of great significance for the development of new drugs and treatment options.

MCM2 is also a potential drug target. Researchers are exploring the role of MCM2 in tumor treatment and looking for drugs that inhibit MCM2 expression. These drugs can include antihistamines, antineoplastic drugs, and anti-inflammatory drugs. In addition, researchers are exploring new ways to use MCM2 as a therapeutic target. For example, the expression of MCM2 can be inhibited by injecting the MCM2 gene, or MCM2 can be used as a vaccine to induce the body to produce an immune response to it, thereby achieving the purpose of treating tumors.

The role of MCM2 in tumor treatment does not stop there. It is also related to tumor invasion and metastasis. Studies have shown that the expression level of MCM2 is closely related to the invasion and metastasis ability of tumors. Therefore, studying the role of MCM2 in tumor invasion and metastasis is of great significance for understanding the molecular mechanisms of tumors and providing more effective targets for tumor treatment.

In summary, MCM2 is a very important protein that plays a key role in the occurrence and development of tumors. By studying the role of MCM2 in tumor treatment, we can better understand the molecular mechanism of tumors and provide more effective targets for tumor treatment. At the same time, MCM2 is also a potential drug target. By inhibiting MCM2 expression, various cancers can be treated.

Protein Name: Minichromosome Maintenance Complex Component 2

Functions: Acts as component of the MCM2-7 complex (MCM complex) which is the replicative helicase essential for 'once per cell cycle' DNA replication initiation and elongation in eukaryotic cells. Core component of CDC45-MCM-GINS (CMG) helicase, the molecular machine that unwinds template DNA during replication, and around which the replisome is built (PubMed:32453425, PubMed:34694004, PubMed:34700328, PubMed:35585232). The active ATPase sites in the MCM2-7 ring are formed through the interaction surfaces of two neighboring subunits such that a critical structure of a conserved arginine finger motif is provided in trans relative to the ATP-binding site of the Walker A box of the adjacent subunit. The six ATPase active sites, however, are likely to contribute differentially to the complex helicase activity (PubMed:32453425). Required for the entry in S phase and for cell division (PubMed:8175912). Plays a role in terminally differentiated hair cells development of the cochlea and induces cells apoptosis (PubMed:26196677)

The "MCM2 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about MCM2 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets

MCM3 | MCM3AP | MCM3AP-AS1 | MCM4 | MCM5 | MCM6 | MCM7 | MCM8 | MCM8-MCM9 complex | MCM9 | MCMBP | MCMDC2 | MCOLN1 | MCOLN2 | MCOLN3 | MCPH1 | MCPH1-AS1 | MCPH1-DT | MCRIP1 | MCRIP2 | MCRS1 | MCTP1 | MCTP2 | MCTS1 | MCTS2 | MCU | MCUB | MCUR1 | MDC1 | MDFI | MDFIC | MDGA1 | MDGA2 | MDH1 | MDH1B | MDH2 | MDK | MDM1 | MDM2 | MDM4 | MDN1 | MDS2 | ME1 | ME2 | ME3 | MEA1 | MEAF6 | MEAF6P1 | MEAK7 | Mechanoelectrical transducer (MET) channel | Mechanosensitive Ion Channel | MECOM | MECOM-AS1 | MeCP1 histone deacetylase (HDAC) complex | MECP2 | MECR | MED1 | MED10 | MED11 | MED12 | MED12L | MED13 | MED13L | MED14 | MED14P1 | MED15 | MED15P8 | MED16 | MED17 | MED18 | MED19 | MED20 | MED21 | MED22 | MED23 | MED24 | MED25 | MED26 | MED27 | MED28 | MED29 | MED30 | MED31 | MED4 | MED4-AS1 | MED6 | MED7 | MED8 | MED9 | MEDAG | Mediator Complex | Mediator of RNA Polymerase II Transcription | MEF2A | MEF2B | MEF2C | MEF2C-AS1 | MEF2C-AS2 | MEF2D | MEFV | MEG3